trimetrexate has been researched along with Cancer, Second Primary in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results would support consideration of a phase II study to determine the effectiveness of trimetrexate for recurrent intra-ocular retinoblastoma." | 3.74 | Impairments in antifolate transport are common in retinoblastoma tumor samples. ( Abramson, DH; Dunkel, IJ; Gorlick, RG; Mazza, BA; Sowers, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gorlick, RG | 1 |
| Abramson, DH | 1 |
| Sowers, R | 1 |
| Mazza, BA | 1 |
| Dunkel, IJ | 1 |
1 other study available for trimetrexate and Cancer, Second Primary
| Article | Year |
|---|---|
Impairments in antifolate transport are common in retinoblastoma tumor samples.
Topics: Adolescent; Antimetabolites, Antineoplastic; Binding, Competitive; Biological Transport; Child; Drug | 2008 |